Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.56 USD | +1.70% | +1.23% | -16.29% |
01:14pm | Earnings Flash (INCY) INCYTE Posts Q1 Revenue $880.9M, vs. Street Est of $924.6M | MT |
01:11pm | Earnings Flash (INCY) INCYTE Posts Q1 EPS $0.64, vs. Street Est of $0.83 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.29% | 11.8B | B- | ||
-3.45% | 87.17B | A- | ||
+1.97% | 40.1B | A- | ||
+57.54% | 25.12B | A | ||
-14.82% | 15.59B | C | ||
-8.82% | 12B | D+ | ||
-41.58% | 11.8B | B | ||
+6.89% | 8.81B | B+ | ||
-10.53% | 8.24B | B- | ||
+0.95% | 7.62B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INCY Stock
- Ratings Incyte Corporation